Organon & Co. Earnings Per Share (Diluted)
Organon & Co. (OGN) reported Earnings Per Share (Diluted) of $0.40 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-07-31
- Organon & Co. earnings per share, diluted for the quarter ending 2026-06-30 was $0.40, a 28.57% decline year-over-year.
- Organon & Co. earnings per share, diluted for the quarter ending 2026-03-31 was $0.55, a 66.67% increase year-over-year.
- Organon & Co. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.78, a 287.11% decline year-over-year.
- Organon & Co. earnings per share, diluted for the quarter ending 2025-09-30 was $0.61, a 55.80% decline year-over-year.
- Organon & Co. earnings per share, diluted for fiscal 2025 was $0.72, a 78.38% decline from fiscal 2024.
- Organon & Co. earnings per share, diluted for fiscal 2024 was $3.33, a 16.54% decline from fiscal 2023.
- Organon & Co. earnings per share, diluted for fiscal 2023 was $3.99, a 11.14% increase from fiscal 2022.
- Organon & Co. earnings per share, diluted for fiscal 2022 was $3.59, a 32.39% decline from fiscal 2021.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.40 10-Q · filed 2026-07-31 | $0.95 10-Q · filed 2026-07-31 | $0.19 derived: net income ÷ weighted average shares · filed 2026-07-31 | $0.79 derived: net income ÷ weighted average shares · filed 2026-07-31 |
| 2026-03-31 | $0.55 10-Q · filed 2026-05-04 | -$0.23 derived: net income ÷ weighted average shares · filed 2026-05-04 | $0.39 derived: net income ÷ weighted average shares · filed 2026-05-04 | $0.94 derived: net income ÷ weighted average shares · filed 2026-07-31 |
| 2025-12-31 | -$0.78 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-04-24 | $0.38 derived: net income ÷ weighted average shares · filed 2026-07-31 | $0.72 10-K · filed 2026-02-24 |
| 2025-09-30 | $0.61 10-Q · filed 2025-11-10 | $1.17 derived: net income ÷ weighted average shares · filed 2026-07-31 | $1.50 10-Q · filed 2025-11-10 | $1.92 derived: net income ÷ weighted average shares · filed 2026-07-31 |
| 2025-06-30 | $0.56 10-Q · filed 2026-07-31 | $0.89 10-Q · filed 2026-07-31 | $1.31 derived: net income ÷ weighted average shares · filed 2026-07-31 | $2.69 derived: net income ÷ weighted average shares · filed 2026-07-31 |
| 2025-03-31 | $0.33 10-Q · filed 2026-05-04 | $0.75 derived: net income ÷ weighted average shares · filed 2026-05-04 | $2.13 derived: net income ÷ weighted average shares · filed 2026-05-04 | $2.89 derived: net income ÷ weighted average shares · filed 2026-05-04 |
| 2024-12-31 | $0.42 derived: net income ÷ weighted average shares · filed 2026-04-24 | $1.80 derived: net income ÷ weighted average shares · filed 2026-04-24 | $2.56 derived: net income ÷ weighted average shares · filed 2026-04-24 | $3.33 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.38 10-Q · filed 2025-11-10 | $2.14 derived: net income ÷ weighted average shares · filed 2025-11-10 | $2.92 10-Q · filed 2025-11-10 | $5.04 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2024-06-30 | $0.75 10-Q · filed 2025-08-06 | $1.53 10-Q · filed 2025-08-06 | $3.65 derived: net income ÷ weighted average shares · filed 2026-04-24 | $3.88 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2024-03-31 | $0.78 10-Q · filed 2025-05-02 | $2.90 derived: net income ÷ weighted average shares · filed 2026-04-24 | $3.13 derived: net income ÷ weighted average shares · filed 2026-04-24 | $4.08 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2023-12-31 | $2.13 derived: net income ÷ weighted average shares · filed 2026-04-24 | $2.36 derived: net income ÷ weighted average shares · filed 2026-04-24 | $3.30 derived: net income ÷ weighted average shares · filed 2026-04-24 | $3.99 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.23 10-Q · filed 2024-11-01 | $1.17 derived: net income ÷ weighted average shares · filed 2024-11-01 | $1.86 10-Q · filed 2024-11-01 | $2.29 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2023-06-30 | $0.95 10-Q · filed 2024-08-07 | $1.64 10-Q · filed 2024-08-07 | $2.06 derived: net income ÷ weighted average shares · filed 2026-04-24 | $2.95 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2023-03-31 | $0.69 10-Q · filed 2024-05-03 | $1.11 derived: net income ÷ weighted average shares · filed 2026-04-24 | $2.00 derived: net income ÷ weighted average shares · filed 2026-04-24 | $2.92 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2022-12-31 | $0.42 derived: net income ÷ weighted average shares · filed 2026-04-24 | $1.31 derived: net income ÷ weighted average shares · filed 2026-04-24 | $2.23 derived: net income ÷ weighted average shares · filed 2026-04-24 | $3.59 10-K/A · filed 2025-11-10 |
| 2022-09-30 | $0.89 10-Q · filed 2023-11-03 | $1.81 derived: net income ÷ weighted average shares · filed 2023-11-03 | $3.17 10-Q · filed 2023-11-03 | $3.96 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2022-06-30 | $0.92 10-Q · filed 2023-08-09 | $2.28 10-Q · filed 2023-08-09 | $3.07 derived: net income ÷ weighted average shares · filed 2026-04-24 | $4.34 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2022-03-31 | $1.36 10-Q · filed 2023-05-05 | $2.16 derived: net income ÷ weighted average shares · filed 2026-04-24 | $3.43 derived: net income ÷ weighted average shares · filed 2026-04-24 | $5.11 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2021-12-31 | $0.79 derived: net income ÷ weighted average shares · filed 2026-04-24 | $2.06 derived: net income ÷ weighted average shares · filed 2026-04-24 | $3.74 derived: net income ÷ weighted average shares · filed 2026-04-24 | $5.31 10-K · filed 2024-02-26 |
| 2021-09-30 | $1.27 10-Q · filed 2022-11-04 | $2.95 derived: net income ÷ weighted average shares · filed 2022-11-04 | $4.52 10-Q · filed 2022-11-04 | $5.98 derived: net income ÷ weighted average shares · filed 2023-02-27 |
| 2021-06-30 | $1.68 10-Q · filed 2022-08-05 | $3.25 10-Q · filed 2022-08-05 | $4.71 derived: net income ÷ weighted average shares · filed 2023-02-27 | $6.87 derived: net income ÷ weighted average shares · filed 2023-02-27 |
| 2021-03-31 | $1.58 10-Q · filed 2022-05-06 | $3.03 derived: net income ÷ weighted average shares · filed 2023-02-27 | $5.18 derived: net income ÷ weighted average shares · filed 2023-02-27 | $7.32 derived: net income ÷ weighted average shares · filed 2023-02-27 |
| 2020-12-31 | $1.45 derived: net income ÷ weighted average shares · filed 2023-02-27 | $3.61 derived: net income ÷ weighted average shares · filed 2023-02-27 | $5.75 derived: net income ÷ weighted average shares · filed 2023-02-27 | $8.52 10-K · filed 2023-02-27 |
| 2020-09-30 | $2.16 10-Q · filed 2021-11-12 | $4.30 derived: net income ÷ weighted average shares · filed 2021-11-12 | $7.07 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $2.14 10-Q · filed 2021-08-16 | $4.91 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $2.78 10-Q · filed 2021-06-21 | |||
| 2019-12-31 | $12.69 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |